Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry
| Autor: | Marco, Sebastiani, Vincenzo, Venerito, Serena, Bugatti, Chiara, Bazzani, Martina, Biggioggero, Luca, Petricca, Rosario, Foti, Alessandra, Bortoluzzi, Silvia, Balduzzi, Elisa, Visalli, Bruno, Frediani, Andreina, Manfredi, Elisa, Gremese, Ennio, Favalli, Florenzo, Iannone, Gianfranco, Ferraccioli, Giovanni, Lapadula, Giuseppe, Lopalco |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Drug
medicine.medical_specialty media_common.quotation_subject Antibodies Monoclonal Humanized Antibodies NO Abatacept TNF inhibitors 03 medical and health sciences chemistry.chemical_compound Retention rate Rheumatoid arthritis Rituximab Tocilizumab Humans Italy Registries Antirheumatic Agents Biological Products 0302 clinical medicine Rheumatology Internal medicine Monoclonal medicine 030212 general & internal medicine Humanized media_common 030203 arthritis & rheumatology business.industry General Medicine medicine.disease chemistry business medicine.drug |
| Popis: | EULAR recommendations do not suggest which biologic disease-modifying anti-rheumatic drug (bDMARD) should be preferred after failure of a first bDMARD in the treatment of rheumatoid arthritis (RA). In particular, few data are available regarding the effectiveness of a second-line bDMARD after failure of abatacept (ABA), tocilizumab (TCZ), and rituximab (RTX). The aim of this study was to analyze the retention rate of a second line with tumor necrosis factor inhibitors (TNFi) or other mechanisms of action (MoAs), after the failure of either RTX, TCZ, or ABA.Two hundred and seventy-eight RA patients from the Italian GISEA registry were included in the study. RTX was the first bDMARD in 18% of patients, ABA in 45.7%, and TCZ in 36.3%, while the second bDMARD was a TNFi (group 1) in 129 patients and an agent with a different MoA (group 2) in 149.During a median follow-up of 22 months (IQR 68), 129 patients discontinued their treatment; patients of group 1 discontinued the treatment more frequently than patients of group 2 (p0.001) with retention rates of 33.6±5.7% and 63.6±4.6% after 104 weeks for group 1 and group 2, respectively (p0.001). At multivariate analysis, the mechanism of action was the only predictor for the maintenance in therapy.According to our data, ABA, RTX, and TCZ seem to maintain a good retention rate also when used as a second-line therapy, suggesting their use after the failure of a non-TNFi as first-line therapy. However, specifically designed studies are needed to evaluate the more appropriate therapeutic strategies in RA, according to the first-line drug, including new targeted synthetic DMARDs. Key Points • A large proportion of rheumatoid arthritis patients fail the first biologic DMARD. • Few data are available about the efficacy of biologic DMARD after the failure of a non-TNF inhibitor. • Abatacept, rituximab, or tocilizumab seem to maintain a good retention rate after the failure of a first-course therapy with a non-TNF inhibitor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|